The burgeoning popularity of tirzepatide , initially for blood sugar control , is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Availability these treatments remains a complex challenge , with public healthcare system coverage currently limited and independent providers offering therapy at a